A PHASE 3, RANDOMIZED, MULTI-CENTER, OPEN-LABEL STUDY OF DB-1303 VERSUS
INVESTIGATOR¿S CHOICE CHEMOTHERAPY IN HUMAN EPIDERMAL GROWTH FACTOR
RECEPTOR 2 (HER2)-LOW, HORMONE RECEPTOR POSITIVE (HR+) METASTATIC BREAST
CANCER PATIENTS WHOSE DISEASE HAS PROGRESSED ON ENDOCRINE THERAPY (ET)
(DYNASTY-BREAST02)
- Registry ID
- DB-1303-O-3002
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE3
- Study type
- INTERVENTIONAL
- Sponsor
- DUALITYBIO INC
- Start date
- 2024-06-11
- Last update
- 2023-12-01
Conditions
- BREAST CANCER HER2-POSITIVE
- BREAST CANCER METASTATIC
Related clinical trials
- A TWO-PART, SEAMLESS, MULTICENTER, RANDOMIZED, OPEN-LABEL, ADAPTIVE PHASE II/III STUDY OF THE BLOOD-BRAIN BARRIER PENETRANT RO7771950 VERSUS TUCATINIB, BOTH IN COMBINATION WITH TRASTUZUMAB AND CAPECITABINE, IN PATIENTS WITH PRETREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC HER2-POSITIVE BREAST CANCER, WITH OR WITHOUT CENTRAL NERVOUS SYSTEM METASTASES
- HERTHENA-BREAST-01: A PHASE 1B/2, MULTICENTER, OPEN-LABEL, DOSE FINDING
STUDY TO EVALUATE THE SAFETY AND ANTITUMOR ACTIVITY OF PATRITUMAB
DERUXTECAN IN PARTICIPANTS WITH HER2 POSITIVE UNRESECTABLE LOCALLY
ADVANCED BREAST CANCER OR METASTATIC BREAST CANCER
- A RANDOMIZED, OPEN-LABEL STUDY COMPARING THE BRIA-IMT REGIMEN IN COMBINATION WITH CHECK POINT INHIBITOR VS PHYSICIAN'S CHOICE IN METASTATIC BREAST CANCER
- A PHASE 3, RANDOMIZED, OPEN-LABEL, MULTICENTER, CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ZANIDATAMAB IN COMBINATION WITH PHYSICIAN¿S CHOICE CHEMOTHERAPY COMPARED TO TRASTUZUMAB IN COMBINATION WITH PHYSICIAN'S CHOICE CHEMOTHERAPY FOR THE TREATMENT OF PARTICIPANTS WITH METASTATIC HER2-POSITIVE BREAST CANCER WHO HAVE PROGRESSED ON, OR ARE INTOLERANT TO, PREVIOUS TRASTUZUMAB DERUXTECAN TREATMENT
- A PHASE 1B/2 OPEN-LABEL STUDY OF DISITAMAB VEDOTIN MONOTHERAPY OR IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS
- TUCATINIB, TRASTUZUMAB AND CAPECITABINE WITH BRAIN AND/OR SPINAL RADIOTHERAPY (XRT) IN PATIENTS WITH HER2+, HER2 MUTATED AND/OR HER2- AMPLIFIED METASTATIC BREAST CANCER AND LEPTOMENINGEAL DISEASE: A MULTI-CENTRE PHASE II, SINGLE ARM FEASIBILITY STUDY.
View on source registry